{"organizations": [], "uuid": "45bd03a7123598034730de72c393b47959a720b1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000551/device/rss", "section_title": "California", "url": "https://www.cnbc.com/2018/02/07/reuters-america-update-1-u-s-fda-approves-gileads-biktarvy-triple-hiv-drug.html", "country": "US", "domain_rank": 767, "title": "UPDATE 1-U.S. FDA approves Gilead's Biktarvy triple HIV drug", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-07T22:55:00.000+02:00", "replies_count": 0, "uuid": "45bd03a7123598034730de72c393b47959a720b1"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/02/07/reuters-america-update-1-u-s-fda-approves-gileads-biktarvy-triple-hiv-drug.html", "ord_in_thread": 0, "title": "UPDATE 1-U.S. FDA approves Gilead's Biktarvy triple HIV drug", "locations": [], "entities": {"persons": [{"name": "descovy", "sentiment": "none"}, {"name": "biktarvy", "sentiment": "none"}, {"name": "brian abrahams", "sentiment": "none"}], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "u.s. food and drug administration", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "gilead", "sentiment": "negative"}, {"name": "guggenheim securities", "sentiment": "none"}, {"name": "glaxosmithkline plc", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "gilead sciences inc", "sentiment": "none"}, {"name": "rbc capital markets", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "(Adds details, analyst comment, share price)\nFeb 7 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Biktarvy, Gilead Sciences Inc's once-daily triple-combination tablet for treatment of HIV infection.\nBiktarvy combines new integrase inhibitor bictegravir with Descovy, an older medication that combines nucleoside reverse transcriptase inhibitors emtricitabine and tenofovir alafenamide.\nThe approval helps \"set the stage for long-term growth and sustainability of Gilead's core HIV franchise,\" RBC Capital Markets analyst Brian Abrahams said in a research note.\nBiktarvy will compete with GlaxoSmithKline Plc's Triumeq.\nThe Gilead drug's wholesale price, about $36,000 a year, is in line with current therapies, according to Guggenheim Securities.\nThe new drug's label includes a boxed warning that use could worsen hepatitis B infection in certain patients.\nWall Street analysts, on average, forecast Biktarvy sales of around $1 billion this year, rising to a peak of nearly $5 billion annually by 2024, according to Thomson Reuters I/B/E/S.\nShares of Gilead, which reported better-than-expected adjusted fourth-quarter profits on Tuesday, were up $3.56, or 4.4 percent, at $83.94 in late trading on Nasdaq.\n(Reporting by Deena Beasley in Los Angeles; Editing by Lisa Shumaker)", "external_links": [], "published": "2018-02-07T22:55:00.000+02:00", "crawled": "2018-02-08T00:13:49.016+02:00", "highlightTitle": ""}